PRISM-MEL-301
Tests whether a PRAME-directed T-cell engager adds to first-line immunotherapy in ordinary skin melanoma, following tebentafusp's success in the eye form.
Phase 3 launched 2024. Supporting phase 1/2 data (ASCO 2026): in 66 heavily pretreated patients on monotherapy, median OS 14.3 months with 57% alive at 12 months; the 160 µg dose was carried into phase 3. PRAME is expressed in most cutaneous melanomas, giving a broader target than gp100.
Pages like this
not linked directly; found by shared links- TrialIMCgp100-202
Shares Immunocore, CD3, T-cell engagers (bispecific), Melanoma.
- IdeaTCR therapeutics for non-HLA-A*02 patients
Shares Brenetafusp, PRAME, T-cell engagers (bispecific), Melanoma.
- ProductTebentafusp
Shares Immunocore, Brenetafusp, CD3, T-cell engagers (bispecific).
- CancerUveal melanoma
Shares Immunocore, Brenetafusp, PRAME, CD3.
- TermHLA-A*02:01 restriction
Shares Brenetafusp, PRAME, T-cell engagers (bispecific), Melanoma.
- InstitutionOxford Cancer – Oxford University Hospitals and University of Oxford
Shares Immunocore, T-cell engagers (bispecific), Melanoma.
- CompanyXencor
Shares CD3, T-cell engagers (bispecific).
- TrialTOWER
Shares CD3, T-cell engagers (bispecific).